1. Home
  2. CAVA vs VTRS Comparison

CAVA vs VTRS Comparison

Compare CAVA & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CAVA Group Inc.

CAVA

CAVA Group Inc.

HOLD

Current Price

$59.64

Market Cap

7.2B

ML Signal

HOLD

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$12.45

Market Cap

14.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAVA
VTRS
Founded
2006
1961
Country
United States
United States
Employees
N/A
30000
Industry
Restaurants
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.2B
14.2B
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
CAVA
VTRS
Price
$59.64
$12.45
Analyst Decision
Buy
Hold
Analyst Count
19
6
Target Price
$78.84
$11.50
AVG Volume (30 Days)
3.5M
8.1M
Earning Date
11-04-2025
11-06-2025
Dividend Yield
N/A
3.90%
EPS Growth
151.16
N/A
EPS
1.16
N/A
Revenue
$1,132,074,000.00
$14,124,400,000.00
Revenue This Year
$24.00
N/A
Revenue Next Year
$20.42
$1.18
P/E Ratio
$51.88
N/A
Revenue Growth
23.93
N/A
52 Week Low
$43.41
$6.85
52 Week High
$144.49
$12.68

Technical Indicators

Market Signals
Indicator
CAVA
VTRS
Relative Strength Index (RSI) 65.79 77.10
Support Level $51.52 $10.67
Resistance Level $62.16 $12.49
Average True Range (ATR) 2.13 0.31
MACD 0.91 0.07
Stochastic Oscillator 79.09 94.33

Price Performance

Historical Comparison
CAVA
VTRS

About CAVA CAVA Group Inc.

Cava Group Inc owns and operates a chain of restaurants. It is the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. The company's dips, spreads, and dressings are centrally produced and sold in grocery stores. The company's operations are conducted as two reportable segments: CAVA and Zoes Kitchen. The company generates all of its revenue from the CAVA segment.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: